Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (34)

2024

  1. Delphi consensus for the third-line treatment of metastatic colorectal cancer

    Clinical and Translational Oncology

  2. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Journal of Clinical Oncology, Vol. 42, Núm. 24, pp. 2918-2927

2023

  1. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 32-44

  2. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  3. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 11, pp. 2107-2119

  3. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554

  4. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

    ESMO Open, Vol. 7, Núm. 3

2021

  1. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

    Scientific Reports, Vol. 11, Núm. 1

  2. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  3. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 4, pp. 273-284

  4. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1520-1528

  5. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

    European Journal of Cancer, Vol. 145, pp. 158-167

2020

  1. Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma

    Translational Oncology, Vol. 13, Núm. 7

  2. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. 165-177

  3. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1160-1168

2019

  1. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

    Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131

  2. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: The ULTRA trial

    Annals of Oncology, Vol. 30, Núm. 5, pp. 796-803

  3. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435